Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SZ011 in Ovarian Epithelial Carcinoma
NCT05856643Phase 1Recruiting
- Sponsor
- Shantou University Medical College
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SZ011 CAR-NK in ovarian epithelial carcinoma, sponsored by Shantou University Medical College. Primary endpoints: Number of Adverse Events, Objective Response Rate and 2 more. Started Aug 2024; status: recruiting.
02
Drugs
SZ011 CAR-NK
03
Conditions
ovarian epithelial carcinoma
Beyond the preview
Go deeper on NCT05856643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856643.